ArticleDiscover oncology2025
Dynamics of mitochondrial DNA copy number regulation in relation to gastric cancer survival.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- New Functions of Mitochondrial Dysfunction in Gastric Cancer: From Molecular Processes to Potential Treatments.International journal of molecular sciences · 2026Review
- Mitochondrial Dysfunction: From Molecular Mechanisms to Modern Approaches for Basic and Clinical Research.Biomedicines · 2026Review
- Genetic Variants in BER Pathway Genes Confer Wilms Tumor Susceptibility: New Insights from an Eight-Center Case-Control Study in Chinese Children.Annals of surgical oncology · 2026Article
- Mitochondrial Stress inAntioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo investigate the causal effects of gene expression levels associated with mitochondrial DNA copy number (mtDNA-CN) on cancer survival outcomes.
methodsWe performed two-sample mendelian randomization (MR) analyses to evaluate the causal relationship between mtDNA-CN in peripheral blood and overall survival period of different cancer types. Additionally, colocalization analyses were performed to identify genes whose expression correlates with mtDNA-CN. Furthermore, we investigated how expression levels of these genes impact survival period in different cancers.
resultsHigher mtDNA-CN in peripheral blood is significantly associated with reduced survival period in gastric cancer (HR = 72.97, 95% CI 68.86 to 77.08, p = 0.046). Colocalization analysis identified six genes, PNP, CDK10, C7orf73, NLRP2, MYO15A, and OSGEP, that regulate the mtDNA-CN in stomach tissue. Among them, higher expressions of MYO15A, OSGEP, and CDK10 are significantly associated with shorter gastric cancer survival. Notably, the impact of OSGEP expression on survival was particularly significant in the ERBB2 amplified subgroup (p = 0.025). Enrichment analysis suggests that the risk genes impact overall survival in gastric cancer prognosis by modulating mitochondrial function and DNA copy number.
conclusionHigher mtDNA-CN in peripheral is correlated with the shorter overall survival in gastric cancer patient. Higher expression of MYO15A, OSGEP, and CDK10 is associated with shorter survival in gastric cancer patients, potentially by regulating mtDNA-CN, suggesting potential targets for future therapeutic interventions of gastric cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.